Anti-mullerian hormone attenuates insulin resistance and systemic inflammation in old obese C57BL/6 male mice.

Purpose: Epidemiological studies show that Anti-mullerian hormone (AMH) is inversely correlated with age, obesity-related diseases, and all-cause mortality in men. To further investigate the role of AMH in aging and obesity, we studied the effect of AMH treatment on the inflammatory and metabolic parameters and weight in old male C57BL/6 mice.

Method: Thirty-six old male C57BL/6 mice (18 month-old) were either on the High-Fat Diet (HFD) or Normal Diet (ND). When obesity occurred in the HFD group, each group was divided into two subgroups; AMH-treated (ND and HFD) or controls (ND and HFD). The AMH subgroup received 15 ng/gbw of recombinant AMH injection every 48 h in four weeks. Then, serum AMH, CRP, fasting glucose, fasting insulin, and HOMA-IR were measured and analyzed.

Results: AMH injection decreased CRP level (HFD =622.86±25.73, HFD =543.2±24.99 ng/ml, = 0.003), fasting insulin (HFD=1.50± 0.34, HFD =0.8±0.25 ng/ml, =0.006) and HOMA-IR (HFD=12.76± 2.88, HFD =7.06±2.31, =0.008) in the obese old mice comparison with control. In ND group, just CRP levels dropped following AMH injection (ND=451.24±20.61, ND= 326.8±23.76 ng/ml; =0.001). Accelerated weight gain was observed in HFD compared with the HFD subgroup (<0.05).

Conclusions: In conclusion, increasing the circulating level of AMH could subside the systemic inflammation through decreasing CRP levels regardless of diet type and enhance insulin sensitivity in old obese mice. It can also lead to higher weight gain, without inflammation, in old obese male mice who are on an HFD.